Gene: SLC35A2
Official Full Name: solute carrier family 35 member A2provided by HGNC
Gene Summary: This gene encodes a member of the nucleotide-sugar transporter family. The encoded protein is a multi-pass membrane protein. It transports UDP-galactose from the cytosol into Golgi vesicles, where it serves as a glycosyl donor for the generation of glycans. Mutations in this gene cause congenital disorder of glycosylation type IIm (CDG2M). Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Oct 2014]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO02813 | SLC35A2 Knockout cell line (HeLa) | Human | SLC35A2 | 1:3~1:6 | Negative | Online Inquiry |
KO02814 | SLC35A2 Knockout cell line (HCT 116) | Human | SLC35A2 | 1:2~1:4 | Negative | Online Inquiry |
KO02815 | SLC35A2 Knockout cell line (HEK293) | Human | SLC35A2 | 1:3~1:6 | Negative | Online Inquiry |
KO02816 | SLC35A2 Knockout cell line (A549) | Human | SLC35A2 | 1:3~1:4 | Negative | Online Inquiry |
SLC35A2 Gene Knockout Cell Lines are specifically engineered cellular models that lack functional expression of the SLC35A2 gene, which encodes a protein involved in nucleotide sugar transport. These knockout cell lines serve as essential tools for probing the biological roles of the SLC35A2 protein, facilitating deeper understanding of cellular metabolism and the mechanisms underlying various diseases. The deletion of this gene enables researchers to study the effects of compromised nucleotide sugar transport on glycosylation pathways, which are crucial for protein and lipid modifications that affect cell signaling, immune responses, and overall cellular health.
The key mechanism of action for SLC35A2 knockout cell lines lies in their drastically altered glycosylation patterns, providing insights into how these modifications influence cellular functions and the potential pathophysiological roles in conditions such as congenital disorders of glycosylation and certain cancers. Their use in research settings allows scientists to identify novel therapeutic targets and conduct high-throughput drug screenings with a greater focus on glycan-related pathways.
Compared to conventional wild-type cell lines, SLC35A2 knockout models offer unparalleled specificity for studies involving glycosylation. Other genomic editing methods, such as CRISPR/Cas9, may introduce off-target mutations; however, these knockout lines provide definitive loss-of-function models essential for high-fidelity research.
For researchers and clinicians alike, leveraging SLC35A2 knockout cell lines is invaluable, as they enhance experimental reproducibility and accuracy in studying the impact of targeted gene loss on cellular and molecular functions. These models can significantly accelerate the process of drug discovery and help establish innovative therapeutic strategies aimed at diseases linked to glycosylation anomalies.
Our company specializes in producing high-quality, validated knockout cell lines, ensuring reliability and reproducibility for your research needs. With extensive expertise in genetic engineering and a commitment to advancing biological research, we provide robust tools to aid your scientific endeavors.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.